Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: April-30-15
Credit Expiration Date: April-30-16

Faculty

Ray Dorsey, MD, MBA
David M. Levy Professor in Neurology, University of Rochester Medical Center
Director, CHET and Center for Health and Technology
University of Rochester Medical Center
Rochester, NY

Daniel Kremens, MD, JD
Associate Professor of Neurology, Sidney Kimmel Medical College at Thomas Jefferson University
Co-Director of the Parkinson’s Disease and Movement Disorders Division
Neurology Clerkship Director, Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, PA

Albert Einstein CCME Reviewer
David Myland Kaufman, MD
Professor, The Saul R. Korey Department of Neurology
Professor, Department of Psychiatry and Behavioral Sciences
Albert Einstein College of Medicine
Bronx, NY

Credit Hours

0.5

Medium

i-Newsletter

Program Description

Approximately 1 million US adults have Parkinson’s disease (PD), a progressive neurodegenerative movement disorder that affects motor and cognitive function and significantly impairs quality of life. PD can be difficult to diagnose, and it is critical that clinicians recognize symptoms, both motor and nonmotor, to aid in early and accurate diagnosis. Appropriate treatment initiation based on patient characteristics, disease progression, and comorbidities is integral to improving patient outcomes in PD. It is also important for clinicians to understand the differences between treatment of early PD and moderate or advanced PD.

Program Developer/Facilitator

This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.

Target Audience

This activity is intended for neurologists, movement disorder specialists, and other clinicians with a neurology specialty including PAs, NPs, and RNs managing patients with PD.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss strategies for improving the early recognition and accurate diagnosis of early PD.
  2. Apply patient-centered care strategies to identify optimal treatment for individual patients with early PD.
  3. Describe recent new evidence for the short- and long-term benefits and risks of treatment options for PD motor symptoms in the early stage of PD.

Disclosures

The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine of Yeshiva University require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine of Yeshiva University (Einstein) also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.

Dr. Dorsey has disclosed the following:
Research support: National Institutes of Health, National Sciences Foundation, David Phinney Foundation, Patient Centered Outcomes Research Institute, Biogen Idec, Prana Biotechnology, Auspex Pharmaceuticals, Michael J. Fox Foundation, Huntington Study Group, Sage Bionetworks
Consultant: Amgen, Avid Radiopharmaceuticals, Clintrex, Lundbeck, Medtronic, National Institute of Neurological Disorders and Stroke, Transparency Life Sciences, MC10, Inc., F. Hoffman-La Roche, Ltd., Shire
Patent: product related to telemedicine and neurology

Dr. Kremens has disclosed the following:
Consultant: AbbVie, Chelsea Therapeutics, Impax, Lundbeck, Merz, US WorldMeds, Teva, UCB
Speakers Bureau: Lundbeck, Merz, US WorldMeds, Teva, UCB
Research Support: Avid Radiopharmaceuticals, Biotie, Civetas

Dr. Kaufman has disclosed the following:
Royalties: Wolters Kluwer, Elsevier
Honoraria: United States Navy

Kelly Andrzejewski, DO, PhD, provided editorial input. She has nothing to disclose.

The staff of the Center for Continuing Medical Education at Albert Einstein College of Medicine and Montefiore Medical Center and MCM Education have nothing to disclose.

Gena Dolson, MCM Education Senior Medical Writer, has nothing to disclose.

Credit Statements

ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine of Yeshiva University designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in each activity.

Credit is awarded to participants who score 80% or better on the post-test.

The online activity will take approximately 30 minutes to complete.

Commercial Support Statements

This activity is supported by independent educational grants from Teva Pharmaceuticals, UCB, and Lundbeck.

Certificate Fee

$0.00

Disclaimer

Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education and MCM Education.

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, MCM Education, Teva Pharmaceuticals, or UCB. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

Data collected in the surveys and polling questions will be used to guide future educational activities and will remain anonymous.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS